** Cardinal Health CAH.N to buy healthcare management firm Solaris Health for $1.9 billion as drug distributor looks to expand its specialty business
** Total quarterly sales came in below analysts' estimates - data compiled by LSEG
BAR WAS HIGH
** Citi ("Neutral", PT:$160) says CAH fell slightly short of high expectations driven by insignificant costs adding up
** Says urology-focused Solaris buy makes "strategic sense" as segment offers more diverse revenue stream, lessens potential most-favored-nation drug pricing risk
** Leerink Partners ("Outperform", PT:$186) says "bar was high" for Cardinal going into Q4 results
** Adds, "quarter was a pause on the back of what's been an incredibly strong multi-year run"
** Morgan Stanley ("Overweight", PT:$190) says heightened expectations for distributors "leaving little or no room for error" dragged CAH shares down post results
** Brokerage says more focus should be on strength in underlying fundamentals across pharma and specialty unit
** J.P.Morgan ("Neutral", PT:$178) says Solaris acquisition would modestly boost guidance in low single-digit increase, but CAH hasn't yet included this in its 2026 outlook
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。